ARK Genomic Revolution ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
ARK Genomic Revolution ETF ARKG
Morningstar’s Analysis ARKG
Will ARKG outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 59.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
10x Genomics Inc Ordinary Shares - Class A | 7.90 | 128M | Healthcare |
Tempus AI Inc Class A common stock | 7.74 | 126M | Healthcare |
Twist Bioscience Corp | 7.41 | 120M | Healthcare |
Personalis Inc | 6.70 | 109M | Healthcare |
CRISPR Therapeutics AG | 6.31 | 102M | Healthcare |
Absci Corp | 6.19 | 100M | Healthcare |
Guardant Health Inc | 4.41 | 72M | Healthcare |
Eli Lilly and Co | 4.39 | 71M | Healthcare |
Beam Therapeutics Inc | 4.22 | 69M | Healthcare |
Illumina Inc | 4.18 | 68M | Healthcare |